Morgan Stanley Starts Kyverna Therapeutics Inc (KYTX) at Overweight, 'Well Positioned in Autoimmune CAR-T Space'
Tweet Send to a Friend
(Updated - March 4, 2024 3:50 AM EST)
Morgan Stanley analyst Michael Ulz initiates coverage on Kyverna Therapeutics Inc ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Morgan Stanley analyst Michael Ulz initiates coverage on Kyverna Therapeutics Inc ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
